News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Changing treatment news

Show

From To
Pharmaceutical industry
GSK touts new Dovato switching data. Is it enough to shake Gilead's HIV lead?

GlaxoSmithKline’s ViiV Healthcare already boasts an approval for Dovato, a two-drug HIV regimen, in newly diagnosed patients. And it just added some new data that aims to at least draw level with market leader Gilead in already-treated patients.

Published
11 July 2019
From
FiercePharma
Changing treatment
Drug-Resistance Mutations May Curb Efficacy of Dolutegravir-Based Regimens in Zimbabwe Teens With HIV

"Public health (officials) should definitely be aware of the implications of drug resistance mutations conferring resistance to tenofovir and/or lamivudine on the activity, efficacy and durability of DTG in such a country, knowing that at present, individual- level HIV drug resistance testing in low and middle income countries (LMICs) is rare and that data are lacking on DTG use in settings with limited or no viral load monitoring."

Published
07 July 2019
From
Medscape (free registration required)
New and experimental HIV treatments
1 Year After Approval: How Does D/C/F/TAF Measure Up?

The US Food and Drug Administration (FDA) approved the first darunavir-based single-tablet regimen (STR) for the treatment of HIV in July 2018. Now, nearly a year since its launch, health care practitioners and patients alike are evaluating its place in the HIV treatment landscape.

Published
01 July 2019
From
Contagion Live
Treatment-experienced people
ART for treatment-experienced people with virological failure can omit NRTIs if three active drugs available

Treatment for HIV-positive individuals with persistent viral replication despite therapy with multiple regimens is effective and safe over two years when it omits nucleoside reverse transcriptase inhibitors

Published
13 June 2019
By
Michael Carter
Health monitoring in resource-limited settings
Significant health gains from faster switching to second-line ART in sub-Saharan Africa

Switching to second-line antiretroviral therapy (ART) after a single viral load measurement above 1000 copies/ml has the potential to save lives, avert a significant burden of AIDS-related illnesses

Published
29 May 2019
By
Michael Carter
Treatment simplification strategies
ViiV Healthcare announces Juluca (dolutegravir/rilpivirine) maintains HIV viral suppression at 148-weeks

SWORD studies demonstrate long-term durable efficacy and tolerability of Juluca, the first complete 2-drug regimen, for the treatment of virologically suppressed adults with HIV

Published
05 April 2019
From
ViiV press release
Changing treatment
Dolutegravir-based second-line ART achieves excellent virological outcomes even in the presence of resistance to recycled NRTIs

Virological response rates were excellent among patients receiving second-line antiretroviral therapy (ART) based on dolutegravir, even when regimens included a nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) to which there

Published
13 March 2019
By
Michael Carter
Treatment simplification strategies
Early ART in HIV Possible Key to Dolutegravir Monotherapy Success

Several randomized controlled trials have shown dolutegravir monotherapy to be inferior to cART. These dolutegravir monotherapy trials, however, have been conducted in patients initiating cART during chronic rather than primary HIV infection. Since patients who start cART during the early phase of HIV infection show a reduced HIV reservoir and low viral diversity, the researchers evaluated whether these properties would allow for sustained virologic suppression after a switch to dolutegravir monotherapy.

Published
15 February 2019
From
Infectious Disease Advisor
Changing treatment
FDA To Consider Pifeltro, Delstrigo as HIV Switch-On Therapies

The FDA will decide this year whether the once-daily Merck therapies can be marketed as a switch-on drug for patients with suppressed HIV-1.

Published
23 January 2019
From
MD Magazine
Treatment outcomes and life expectancy
Atripla or efavirenz plus Truvada failed one in 16 people in first year

Although analyses of the failure rate of ART have been conducted before, a new analysis is the first to compute these rates for a single-drug regimen

Published
21 January 2019
By
Gus Cairns
← First12345...31Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.